Posted on: 23 Aug 22

Qureight today announces its Scientific Advisory Board for Idiopathic Pulmonary Fibrosis (IPF). This progressive scarring lung disease is one of the company’s three benchmark conditions alongside Pulmonary Arterial Hypertension and Non-small cell lung cancer. IPF is a complex disease which is difficult to diagnose and monitor. The Qureight platform has recently been successfully used as a surrogate clinical trial endpoint by analysing and structuring complex data from a phase 2 IPF study (results to be announced at European Respiratory Society meeting in Barcelona on 5th September 2022). Qureight’s platform for IPF and other progressive fibrosing interstitial lung diseases (ILDs) is being rapidly adopted for accelerating clinical trials and developing new and clearer clinical endpoints in these complex diseases.

As the platform becomes more widely used with biopharma partners worldwide, the company has formed this Scientific Advisory Board with leading experts in the field of clinical trial and drug development. CEO Dr. Muhunthan Thillai said: “The bringing together of global IPF experts provides a clear signal that the Qureight platform technology is able to support development of new drugs for IPF. These experts have amongst them been responsible for delivering the current generation of antifibrotic medications and are key leaders in development for the next set of medications with some of our global biopharma partners. We look forward to working with them and shortly adopting our models for data curation in our next set of complex diseases.”

Members of the IPF Scientific Advisory Board:

Dr Bill Bradford

1
Dr Bill Bradford is an independent consultant and well-established scientist in the pharmaceutical industry. Beginning his career practising academic medicine in the Division of Infectious Diseases at the University of California, he has gained over 20 years’ experience in public and private companies. He founded Indalo Therapeutics where he was Chief Medical Officer. Previously he served at InterMune, where he developed Esbriet for IPF. Dr. Bradford now consults on scientific and clinical development with many of the world’s leading biopharma companies.

Dr Paul Ford

1
Dr Paul Ford is a pharmaceutical discovery clinician with a broad background in Respiratory Medicine, pharmaceutical and device medicine, and academic research. He has been essential in advancing projects in several IPF companies including PureTech and Galapagos. He has held complex roles in clinical development and end to end target selection across numerous clinical studies.

Professor Toby Maher

1
Professor Toby Maher is a Professor of Clinical Medicine and Director of ILD at Keck School of Medicine. Previously, he ran the ILD unit at Royal Brompton Hospital, London. Investing many years of his career focusing on the management of pulmonary fibrosis, he also specialises in sarcoidosis and hypersensitivity pneumonitis. Research pursuits include a heavy focus on biomarker discovery, the lung microbiome and host immune response in IPF pathogenesis, and extensive clinical trial management with emphasis on early phase clinical trials. Professor Maher is Associate Editor of the American Journal of Respiratory and Critical Care Medicine.

Professor Phil Molyneaux

1
Professor Phil Molyneaux is the Asthma and Lung UK Chair of Respiratory Research. He is a leading ILD clinician and the director of the NIHR Cardiovascular Clinical Research Facility at the Royal Brompton Hospital. After completing his clinical training and PhD at the Royal Brompton he joined Imperial College London establishing his own research Group. His research focuses on understanding the interaction between the respiratory tract microbiota and innate immunity in pulmonary fibrosis. Prof Molyneaux is a highly experienced clinical trialist, sits on the diffuse lung disease editorial board at Chest and is an advisor to academic and pharmaceutical companies.

Dr Melissa Wickremasinghe

1
Dr Melissa Wickremasinghe trained in Respiratory Medicine at Royal Brompton Hospital and St Mary’s Hospital London, and followed with a PhD in respiratory epithelial cell chemokine networks at Imperial College London. Dr Wickremasinghe has since founded the lung fibrosis and sarcoidosis service at St Mary’s Hospital which is now one of the leading specialist centres in the UK. She is a transformation Chief Clinical Information Officer, an experienced clinical trialist, and has continued research interests in digital healthcare delivery and remote monitoring.